<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610623</url>
  </required_header>
  <id_info>
    <org_study_id>Anb006#2001</org_study_id>
    <nct_id>NCT00610623</nct_id>
  </id_info>
  <brief_title>Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia</brief_title>
  <official_title>Proof of Concept Study to Investigate the Impact of Azithromycin Administered iv Versus Placebo on the Prevention of Pneumonia in Ventilated Patients Colonized by Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anbics Management-Services Ag</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anbics Management-Services Ag</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical efficacy of azithromycin, used as a
      quorum-sensing blocker, when compared to placebo for preventing or delaying the occurrence of
      pneumonia in ventilated patients colonized with Pseudomonas aeruginosa.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The sponsor decided to stop the study prematurely because of financial issues
  </why_stopped>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of and time to Pseudomonas aeruginosa pneumonia</measure>
    <time_frame>daily</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of and time to death</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to extubation</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall outcome</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization and ICU stay</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of infections to other bacterial strains</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost assessment</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>demonstrate using in vitro and in vivo parameters that azithromycin can be used as a quorum-sensing blocker against P. aeruginosa</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine whether prolonged treatment with azithromycin may induce resistance to any of 11 anti-pseudomonal antibiotics</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine whether P. aeruginosa can develop resistance to the quorum-sensing effect of azithromycin</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <condition>Pseudomonas Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>azithromycin iv 300 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>300 mg/day, IV from day 1 to 20</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once per day, IV from day 1 to 20</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non pregnant female aged 18 to 75 years

          -  Patients hospitalized in ICU, under mechanically assisted ventilation expected to be
             mandatory for 3 days or more

          -  Reasonable survival chance within next few days with an Apache score 10-25

          -  Tracheal aspirate found positive for P. aeruginosa

          -  The subject (or a close family member in case of incompetence) understands the
             procedure, agrees to participate, and is willing to give written informed consent

          -  Informed consent must be obtained for all subjects before enrollment in the study, by
             patient or by a close family member

        Exclusion Criteria:

          -  Poor prognosis as judged by Apache score II score &gt;25

          -  Pregnant female

          -  Grossly under-or overweight (BMI&lt;18or &gt;29)

          -  Ongoing therapy with a macrolide

          -  Known allergy to any macrolide

          -  Proven P. aeruginosa pneumonia

          -  Ongoing anti-pseudomonal therapy with a proven susceptible colonizing strain

          -  Anticipated short duration of mechanical ventilation (&lt;3 days)

          -  Known drug interaction that could either decrease efficacy or raise safety concerns

          -  Severe hepatic failure (type C, score &gt;10 on Child Pugh scale)

          -  Sick sinus syndrome or long QT syndrome

          -  Recent donation of blood or participation in another clinical trial within 3 months

          -  Any situation exposing the patient to higher risk or possibly confounding results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Van Delden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service of Infectious Diseases, University Hospital Geneva, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Carlet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>General Intensive Care Unit, Hospital Saint-Joseph, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intensive Care Unit, Clinique Saint-Pierre</name>
      <address>
        <city>Ottignies</city>
        <state>Louvain</state>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Intensive Car Unit, Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Intensive Care Unit, Clinical Center of Serbia, Institut of Neurosurgery</name>
      <address>
        <city>Belgrade</city>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Intensive Care Unit, Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Jean Minjoz University Hospital</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Car Unit, Calmette University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical-surgical intensive car unit, Dupuytren Teaching Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>8700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Intensive Care Unit, Montauban City Hospital</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Car Unit, Hospital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Intensive Car Unit; University Hospital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Intensive Care Unit, Hospital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Wojewodzki Hospital</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Wojewodzki Hospital</name>
      <address>
        <city>Sosnowiec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Central Hospital</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine, Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, San Dureta University Hospital</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Joan XXIII University Hospital</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical and Medical Intensive Care Units, University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Former Serbia and Montenegro</country>
    <country>France</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2008</study_first_posted>
  <last_update_submitted>January 28, 2008</last_update_submitted>
  <last_update_submitted_qc>January 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Christian van Delden</name_title>
    <organization>Service of Infectious Diseases, University Hospital Geneva</organization>
  </responsible_party>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Ventilator-Associated</keyword>
  <keyword>Quorum Sensing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

